SCHEMBL2804345

SCHEMBL2804345

COC(=O)c1ccc(OC)c(/C(N)=N\O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
RECQL P46063 1/20 0.53
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ATM Q13315 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506507 1.00 MAPT (0.56) MAPTRECQLRAB9ANPC1GAA
SCHEMBL9968908 1.00 MAPT (0.56) MAPTRECQLRAB9ANPC1GAA
SCHEMBL2804346 1.00 MAPT (0.56) MAPTRECQLRAB9ANPC1GAA
SCHEMBL30745101 0.88 RECQL (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL28413725 0.88 RECQL (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL25707071 0.88 RECQL (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL2773585 0.88 GAA (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL9968902 0.88 GAA (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL20963465 0.88 RECQL (0.60) MAPTRECQLRAB9ANPC1GAA
SCHEMBL2773580 0.88 GAA (0.60) MAPTRECQLRAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122276-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-06-29 WO disclosed
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 MAPT 3455/4885RECQL 4/4885RAB9A 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.